Suppression of ongoing experimental allergic encephalomyelitis in da rats by novel peptide drug, structural part of human myelin basic protein 4662

Autoimmunity

Volumn 42, Issue 4, 2009, Pages 362-364

  Belogurov Jr , A A ^a,c   Zargarova, T A ^a   Turobov, V I ^a   Novikova, N I ^a   Favorova, O O ^b   Ponomarenko, N A ^a   Gabibov, A G ^a,c  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^b INSTITUTE OF EXPERIMENTAL CARDIOLOGY   (Russian Federation)

^c INSTITUTE OF GENE BIOLOGY   (Russian Federation)

Author keywords

Copaxone ; DA rats; Experimental allergic encephalomyelitis; Multiple sclerosis; Myelin basic protein

Indexed keywords

FREUND ADJUVANT; GLATIRAMER; MYELIN BASIC PROTEIN; MYELIN BASIC PROTEIN[124-139]; MYELIN BASIC PROTEIN[147-170]; MYELIN BASIC PROTEIN[46-62]; MYELIN BASIC PROTEIN[81-102]; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DARK AGOUTI RAT; DISEASE DURATION; DISEASE SEVERITY; DRUG EFFICACY; MULTIPLE SCLEROSIS; NONHUMAN; RAT; TISSUE HOMOGENATE;

ANIMALS; ANTIBODIES, CATALYTIC; AUTOANTIBODIES; AUTOANTIGENS; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; NERVE TISSUE PROTEINS; PEPTIDES; RATS; TRANSCRIPTION FACTORS;

EID: 70749158098     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930902832090     Document Type: Article

References (9)

1. Berger T, et al. Antimyelin antibodies as a predictor of clinically definite multiple sclerosis after a first demyelinating event. N Engl J Med 2003;349(2):139-145.
2. McFarland HF. The B cell-old player, new position on the team. N Engl J Med 2008;358(7):664-665.
3. Ponomarenko NA, et al. Catalytic activity of autoantibodies toward myelin basic protein correlates with the scores on the multiple sclerosis expanded disability status scale. Immunol Lett 2006;103(1):45-50.
4. Ponomarenko NA, et al. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci USA 2006;103(2):281-286.
5. Belogurov AA, Jr, et al. Recognition and degradation of myelin basic protein peptides by serumautoantibodies: Novel biomarker for multiple sclerosis. J Immunol 2008;180(2):1258-1267.
6. Lorentzen JC, et al. Protracted, relapsing and demyelinating experimental autoimmune encephalomyelitis in DA rats immunized with syngeneic spinal cord and incomplete Freund's adjuvant. J Neuroimmunol 1995;63(2):193-205.
7. Teitelbaum D, et al. Oral glatiramer acetate in experimental autoimmune encephalomyelitis: Clinical and immunological studies. Ann NY Acad Sci 2004;1029:239-249.
8. Filippi M, et al. Effects of oral glatiramer acetate on clinical and MRI-monitored disease activity in patients with relapsing multiple sclerosis: A multicentre, double-blind, randomised, placebo-controlled study. Lancet Neurol 2006;5(3):213-220.
9. Xu LY, et al. Suppression of ongoing experimental allergic encephalomyelitis (EAE) in Lewis rats: Synergistic effects of myelin basic protein (MBP) peptide 68-86 and IL-4. Clin Exp Immunol 2000;120(3):526-531.